Caribou Biosciences (CRBU) Operating Leases (2022 - 2026)

Caribou Biosciences (CRBU) has 5 years of Operating Leases data on file, last reported at $25.7 million in Q1 2026.

• Quarterly Operating Leases rose 5.49% year-over-year to $25.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.7 million (up 5.49% YoY) and the FY2025 annual result came in at $26.0 million, up 3.85% from the prior year.
• Operating Leases slipped to $25.7 million in Q1 2026 per CRBU's latest filing, from $26.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $27.9 million in Q3 2022 and bottomed at $22.8 million in Q3 2025.
• The 5-year median for Operating Leases is $26.2 million (2023), against an average of $26.0 million.
• The widest annual swing landed in 2025, when Operating Leases slipped 14.5%; it then rose 5.49% in 2026.
• Tracing CRBU's Operating Leases over 5 years: stood at $26.8 million in 2022, then decreased by 3.26% to $25.9 million in 2023, then decreased by 3.27% to $25.1 million in 2024, then grew by 3.85% to $26.0 million in 2025, then retreated by 1.41% to $25.7 million in 2026.
• Per Business Quant, the three latest CRBU Operating Leases figures stand at $25.7 million (Q1 2026), $26.0 million (Q4 2025), and $22.8 million (Q3 2025).

Peer Comparison